Search research articles
Contact Us
Filters
Showing results (141-150 of 201) with videos related to
Page
of 21
Sort By:
Frontiers in Public Health
|
February 13, 2026
The relevance of Spiritual Leadership to public health: values, meaning and purpose
Louis W Fry, Barbara X Wei, Fawn Phelps, et al.
Journal of Medicinal Chemistry
|
September 1, 1995
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor
G W Rewcastle, W A Denny, A J Bridges, et al.
The Journal of Biological Chemistry
|
June 11, 1998
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway
J M Cunnick, J F Dorsey, T Standley, et al.
Dental Economics - Oral Hygiene
|
December 1, 1978
Planning guide for 1979
P Redmond, W F Mangan, M L Schultz, et al.
Journal of Medicinal Chemistry
|
August 20, 1993
Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)
A M Thompson, G W Rewcastle, M Tercel, et al.
The EMBO Journal
|
May 15, 2002
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
Ami Citri, Iris Alroy, Sara Lavi, et al.
Anti-Cancer Drug Design
|
August 1, 1994
Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity
D W Fry, A J Kraker, R C Connors, et al.
Advances in Enzyme Regulation
|
January 1, 1984
Biochemical pharmacology of the lipophilic antifolate, trimetrexate
R C Jackson, D W Fry, T J Boritzki, et al.
Biochemical Pharmacology
|
April 1, 1985
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)
T J Boritzki, D A Berry, J A Besserer, et al.
Cancer Research
|
September 1, 1991
In vivo and in vitro evaluation of the alkylating agent carmethizole
W L Elliott, D W Fry, W K Anderson, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 201) with videos related to
Sort By:
Page
of 21
Frontiers in Public Health
|
February 13, 2026
The relevance of Spiritual Leadership to public health: values, meaning and purpose
Louis W Fry, Barbara X Wei, Fawn Phelps, et al.
Journal of Medicinal Chemistry
|
September 1, 1995
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor
G W Rewcastle, W A Denny, A J Bridges, et al.
The Journal of Biological Chemistry
|
June 11, 1998
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway
J M Cunnick, J F Dorsey, T Standley, et al.
Dental Economics - Oral Hygiene
|
December 1, 1978
Planning guide for 1979
P Redmond, W F Mangan, M L Schultz, et al.
Journal of Medicinal Chemistry
|
August 20, 1993
Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids)
A M Thompson, G W Rewcastle, M Tercel, et al.
The EMBO Journal
|
May 15, 2002
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
Ami Citri, Iris Alroy, Sara Lavi, et al.
Anti-Cancer Drug Design
|
August 1, 1994
Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity
D W Fry, A J Kraker, R C Connors, et al.
Advances in Enzyme Regulation
|
January 1, 1984
Biochemical pharmacology of the lipophilic antifolate, trimetrexate
R C Jackson, D W Fry, T J Boritzki, et al.
Biochemical Pharmacology
|
April 1, 1985
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)
T J Boritzki, D A Berry, J A Besserer, et al.
Cancer Research
|
September 1, 1991
In vivo and in vitro evaluation of the alkylating agent carmethizole
W L Elliott, D W Fry, W K Anderson, et al.
Page
of 21